Published in Blood Weekly, April 8th, 2004
The company previously released an interim analysis of the Phase III clinical study and discussed its analysis of that data during its February 13th, 2004, conference call.
The interim analysis of the data previously released by the company and relating to the first 45 events revealed that those receiving Dacogen had an increased time to acute myelogenous leukemia (AML) or death...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.